Table 1.
Baseline characteristics of the participants. The data are given as medians and range, n = 6.
| Sex, M/F | 4/2 |
| Age, years | 55.5 (48.0–79.0) |
| BMI, kg/m2 | 29.5 (22.0–32.0) |
| Underlying condition: | |
| Isolated hyper-Lp(a) | 2 |
| Familial hypercholesterolemia (confirmed) | 1 |
| Clinical phenotype of familial hypercholesterolemia | 3 |
| Statin intolerance | 2 |
| Ever smoked, Y/N | 3/3 |
| Coronary artery disease, Y/N | 5/1 |
| Stroke, Y/N | 0/6 |
| Diabetes, Y/N | 0/6 |
| Hypertension, Y/N | 3/3 |
| Time on lipoprotein apheresis, months | 26.5 (19.0–38.0) |
| Lipid profile before commencement of lipoprotein apheresis: | |
| Lp(a), g/L Reference range |
1.1 (0.06–3.1) 0.02–0.74 |
| Total cholesterol, mg/dL Reference range: |
239.5 (191.0–367.0) 115–190 |
| LDL, mg/dL Reference range: |
152.8 (118.0–152.5) <100 |
| HDL, mg/dL Reference range: |
49.0 (39.0–77.0) F > 45; M > 40 |
| Triglycerides, mg/dL Reference range: |
294.5 (187.0–735.0) <150 |
| ApoA1, g/L Reference range: |
1.6 (1.3–1.8) 1.25–2.15 |
| ApoB, g/L Reference range: |
1.1 (0.7–2.0) 0.55–1.25 |
| ApoB/ApoA1 Reference range: |
0.7 (0.4–1.2) 0.3–0.9 |
| Additional medication: | |
| Statins, Y/N | 4/2 |
| Ezetimibe, Y/N | 5/1 |
| Fenofibrate, Y/N | 1/5 |
Abbreviations: Y, yes; N, no; F, female; M, male; BMI, body mass index; Lp(a), lipoprotein(a); HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B.